Table 2.
The role of KDM5B in each type of cancer.
| Type of Cancer | Role | Prognosis | References |
|---|---|---|---|
| ER+ breast cancer | Oncogene | Poor in patients with high KDM5B expression | [8,38,49,93,94,95] |
| Triple-negative breast cancer | Tumor suppressor or Oncogene? | Poor in patients with high KDM5B expression | [20,30,96,97] |
| Melanoma | Oncogene | Poor response to ICB in patients with high KDM5B expression | [44,102,103] |
| Prostate cancer | Oncogene | Poor in patients with high KDM5B expression | [50,106,107,108] |
| Non-small cell lung cancer | Oncogene | Poor in patients with high KDM5B expression | [109,110,111,112] |
| Hepatocellular carcinoma | Oncogene | Poor in patients with high KDM5B expression | [113,120,121] |
| Esophageal cancer | Oncogene | Poor trend in patients with high KDM5B expression | [119,122,123] |
| Gastric cancer | Oncogene | NA | [114] |
| Colorectal cancer | Oncogene | Poor in patients with high KDM5B expression | [115,124,125] |
| Oral cancer | Oncogene | Poor in patients with high KDM5B expression | [116,126] |
| Ewing sarcoma | Oncogene | Poor in patients with high KDM5B expression | [118] |
| Glioma | Oncogene | Poor in patients with high KDM5B expression | [127,128] |
| ALL | Oncogene | NA | [117,129] |
| CML | Oncogene | NA | [32] |
| AML with MLL rearrangement or NUP98–NSD1 | Tumor suppressor | Good in patients with high KDM5B expression | [34,130] |
ER: estrogen receptor; ICB: immune checkpoint blockade; NA: not available; ALL: acute lymphoblastic leukemia; CML: chronic myeloid leukemia; AML: acute myeloid leukemia.